Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
| This article needs additional citations for verification.|
Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (June 2008)
|Gray's||subject #263 1251|
|Prostate with seminal vesicles and seminal ducts, viewed from in front and above.|
The prostate (from Greek προστάτης - prostates, literally "one who stands before", "protector", "guardian") is a compound tubuloalveolar exocrine gland of the male mammalian reproductive system. Women do not have a prostate gland, although women do have microscopic paraurethral Skene's glands connected to the distal third of the urethra in the prevaginal space that are homologous to the prostate.
- Posterior: urethra and rectum
- Superior: upper surface of urogenital diaphragm and urinary bladder
- Lateral: anterior fibers of levator ani muscle
The main function of the prostate is to store and secrete a clear, slightly alkaline (pH 7.29) fluid that constitutes 10-30% of the volume of the seminal fluid that, along with spermatozoa, constitutes semen. The rest of the seminal fluid is produced by the two seminal vesicles. The alkalinity of seminal fluid helps neutralize the acidity of the vaginal tract, prolonging the lifespan of sperm.
Prostatic secretions vary among species. They are generally composed of simple sugars, and are often slightly alkaline.
The main male hormone is testosterone, which is produced mainly by the testicles. Some male hormones are produced in small amounts by the adrenal glands. However, it is dihydrotestosterone that regulates the prostate.
The prostatic part of the urethra develops from the pelvic (middle) part of the urogenital sinus (endodermal origin). Endodermal outgrowths arise from the prostatic part of the urethra and grow into the surrounding mesenchyme. The glandular epithelium of the prostate differentiates from these endodermal cells, and the associated mesenchyme differentiates into the dense stroma and the smooth muscle of the prostate. The prostate glands represent the modified wall of the proximal portion of the male urethra and arises by the 9th week of embryonic life in the development of the reproductive system. Condensation of mesenchyme, urethra and Wolffian ducts gives rise to the adult prostate gland, a composite organ made up of several glandular and non-glandular components tightly fused within a common capsule.
"In 2002, what was once an obscure female anatomical feature known as the paraurethral glands, or Skene's glands, was officially renamed the prostate by the Federative International Committee on Anatomical Terminology." 
The ducts are lined with transitional epithelium.
Within the prostate, the urethra coming from the bladder is called the prostatic urethra and merges with the two ejaculatory ducts. (The male urethra has two functions: to carry urine from the bladder during urination and to carry semen during ejaculation.) The prostate is sheathed in the muscles of the pelvic floor, which contract during the ejaculatory process.
The prostate can be divided in two different ways: by zone, or by lobe.
The "zone" classification is more often used in pathology.
The prostate gland has four distinct glandular regions, two of which arise from different segments of the prostatic urethra:
|Peripheral zone (PZ)||Composes up to 70% of the normal prostate gland in young men||The sub-capsular portion of the posterior aspect of the prostate gland which surrounds the distal urethra. It is from this portion of the gland that more than 70% of prostatic cancers originate.|
|Central zone (CZ)||Constitutes approximately 25% of the normal prostate gland||This zone surrounds the ejaculatory ducts. Central zone tumours account for more than 25% of all prostate cancers.|
|Transition zone (TZ)||Responsible for 5% of the prostate volume||This zone is very rarely associated with carcinoma. The transition zone surrounds the proximal urethra and is the region of the prostate gland which grows throughout life and is responsible for the disease of benign prostatic enlargement.|
|Anterior fibro-muscular zone (or stroma)||Accounts for approximately 5% of the prostatic weight||This zone is usually devoid of glandular components, and composed only, as its name suggests, of muscle and fibrous tissue.|
The "lobe" classification is more often used in anatomy.
|Anterior lobe (or isthmus)||roughly corresponds to part of transitional zone|
|Posterior lobe||roughly corresponds to peripheral zone|
|Lateral lobes||spans all zones|
|Median lobe (or middle lobe)||roughly corresponds to part of central zone|
- Main article: Prostatitis
Prostatitis is inflammation of the prostate gland. There are different forms of prostatitis, each with different causes and outcomes. Acute prostatitis and chronic bacterial prostatitis are treated with antibiotics; chronic non-bacterial prostatitis or male chronic pelvic pain syndrome, which comprises about 95% of prostatitis diagnoses, is treated by a large variety of modalities including alpha blockers, phytotherapy, physical therapy, psychotherapy, antihistamines, anxiolytics, nerve modulators and more. More recently, a combination of trigger point and psychological therapy has proved effective as well.
Benign prostatic hyperplasiaEdit
- Main article: Benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) occurs in older men; the prostate often enlarges to the point where urination becomes difficult. Symptoms include needing to go to the toilet often (pollakisuria) or taking a while to get started (hesitancy). If the prostate grows too large it may constrict the urethra and impede the flow of urine, making urination difficult and painful and in extreme cases completely impossible.
BPH can be treated with medication, a minimally invasive procedure or, in extreme cases, surgery that removes the prostate. Minimally invasive procedures include Transurethral needle ablation of the prostate (TUNA) and Transurethral microwave thermotherapy (TUMT). These outpatient procedures may be followed by the insertion of a temporary Prostatic stent, to allow normal voluntary urination, without exacerbating irritative symptoms.
The surgery most often used in such cases is called transurethral resection of the prostate (TURP or TUR). In TURP, an instrument is inserted through the urethra to remove prostate tissue that is pressing against the upper part of the urethra and restricting the flow of urine. Older men often have corpora amylacea (amyloid), dense accumulations of calcified proteinaceous material, in the ducts of their prostates. The corpora amylacea may obstruct the lumens of the prostatic ducts, and may underlie some cases of BPH.
Urinary frequency due to bladder spasm, common in older men, may be confused with prostatic hyperplasia. Statistical observations suggest that a diet low in fat and red meat and high in protein and vegetables, as well as regular alcohol consumption, could protect against BPH.
- Main article: Prostate cancer
Prostate cancer is one of the most common cancers affecting older men in developed countries and a significant cause of death for elderly men (estimated by some specialists at 3%). Regular rectal exams are recommended for older men to detect prostate cancer early.
Though prostate cancer is of most concern to older men, it is like other cancers, a complex disease with many risk factors; race, age, genetics, and lifestyle habits can all contribute to its development.
Male sexual responseEdit
During orgasm sperm are transmitted from the ductus deferens into the male urethra via the ejaculatory ducts, which lie within the prostate gland. The prostate is often referred to as the "male G-spot". Some men are able to achieve orgasm solely through stimulation of the prostate gland, such as prostate massage or receptive anal intercourse. Men who report the sensation of prostate stimulation often give descriptions similar to women's accounts of G-spot stimulation.
Vasectomy and risk of prostate cancerEdit
In 1993, the Journal of the American Medical Association revealed a connection between vasectomy and an increased risk of prostate cancer. Reported studies of 48,000 and 29,000 men who had vasectomies showed 66 percent and 56 percent higher rates of prostate cancer, respectively. The risk increased with age and the number of years since the vasectomy was performed.
However, in March of the same year, the National Institute of Child Health and Human Development held a conference cosponsored by the National Cancer Institute and others to review the available data and information on the link between prostate cancer and vasectomies. It was determined that an association between the two was very weak at best, and even if having a vasectomy increased one's risk, the risk was relatively small.
In 1997, the NCI held a conference with the prostate cancer Progressive Review Group (a committee of scientists, medical personnel, and others). Their final report, published in 1998 stated that evidence that vasectomies help to develop prostate cancer was weak at best.
Stenting the prostateEdit
Recent scientific breakthroughs have now meant using a Prostatic stent is a viable method of dis-obstructing the prostate. Stents are devices inserted into the urethra to widen it and keep it open. Stents can be temporary or permanent and is mostly done on an outpatient basis under local or spinal anesthesia and usually takes about 30 minutes.
The text of this article was originally taken from NIH Publication No. 02-4806, a public domain resource .
- ↑ The term prostates, Liddell and Scott, "A Greek-English Lexicon", at Perseus
- ↑ Moore and Persaud. Before We Are Born, Essentials of Embryology and Birth Defects, 7th edition. Saunders Elsevier. 2008. ISBN 978-1-4160-3705-7
- ↑ Seattle Times - http://seattletimes.nwsource.com/html/health/2002865111_carnalknowledge15.html
- ↑ Instant Anatomy - Abdomen - Vessels - Veins - Prostatic plexus. URL accessed on 2007-11-23.
- ↑ (2006). Pharmacological treatment options for prostatitis/chronic pelvic pain syndrome. URL accessed on 2006-12-11.
- ↑ Anderson RU, Wise D, Sawyer T, Chan CA (2006). Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J. Urol. 176 (4 Pt 1): 1534–8; discussion 1538–9.
- ↑ Verhamme KM, Dieleman JP, Bleumink GS, et al (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. Eur. Urol. 42 (4): 323–8.
- ↑ Dineen MK, Shore ND, Lumerman JH, Saslawsky MJ, Corica AP (2008). Use of a Temporary Prostatic Stent After Transurethral Microwave Thermotherapy Reduced Voiding Symptoms and Bother Without Exacerbating Irritative Symptoms.. J. Urol. 71 (5): 873–877.
- ↑ Slide 33: Prostate, at ouhsc.edu.
- ↑ Kristal AR, Arnold KB, Schenk JM, et al (April 2008). Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 167 (8): 925–34.
- ↑ Nutritional Prevention of Prostate Cancer, available online at . (Purchase required)
- ↑ Ladas, AK; Whipple, B; Perry, JD . The G spot and other discoveries about human sexuality, New York: Holt, Rinehart, and Winston.
- ↑ Vasectomy and Cancer Risk. National Cancer Institute. URL accessed on 2008-01-08.